Kymera Therapeutics Inc
KYMR
Market Cap$1.95B
Close$
$-9.17
130.5% downside
Current Fair Value
130.5% downsideOvervalued by 130.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.95 Billion |
|---|---|
| Enterprise Value | $1.93 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.98 |
| Beta | 2.19 |
| Outstanding Shares | 79,987,426 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.74 |
|---|---|
| PEG | -59.05 |
| Price to Sales | 30.07 |
| Price to Book Ratio | 3.01 |
| Enterprise Value to Revenue | 22.09 |
| Enterprise Value to EBIT | -10.17 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Kymera Therapeutics Inc
75 employeesKymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted...